Clinical trial
Survival in Adult Patients With BRAF V600 Mutation-Positive Advanced Melanoma: A Non-Interventional Ambispective Study of a Cohort of Patients Treated With Cobimetinib During the French Early Access Program (TAU)
NCT03139513 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Survival in Adult Patients With BRAF V600 Mutation-Positive Advanced Melanoma: A Non-Interventional Ambispective Study of a Cohort of Patients Treated With Cobimetinib During the French Early Access Program (TAU)
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Observational
- Overall status
- Completed
- Start date
- October 27, 2016
- Completion date
- August 22, 2018
- Enrollment
- 200 (estimated)
- Sites
- 33
Conditions
As the registry lists them; a condition with its own page is linked.